

# Choroid Plexus-Selective Inactivation of Adenosine A<sub>2A</sub> Receptors Protects Against T Cell Infiltration And Experimental Autoimmune Encephalomyelitis

**Wu Zheng**

Wenzhou Medical University

**Yijia Feng**

Wenzhou Medical University

**Zhenhai Zeng**

Wenzhou Medical University

**Mengqian Ye**

Wenzhou Medical University

**Huiping Shang**

Wenzhou Medical University

**Mengru Wang**

Wenzhou Medical University

**Xiangxiang Lin**

Wenzhou Medical University

**Xiaoting Sun**

Wenzhou Medical University

**Muran Wang**

Wenzhou Medical University

**Zhengzheng Li**

Wenzhou Medical University

**Yiyun Weng**

Wenzhou Medical University

**Wei Guo**

Wenzhou Medical University

**Sergii Vakal**

Wenzhou Medical University

**jiangfan chen** (✉ [chenjf555@gmail.com](mailto:chenjf555@gmail.com))

Wenzhou Medical University <https://orcid.org/0000-0002-0446-3956>

**Keywords:** adenosine A2A receptor, multiple sclerosis, choroid plexus, immune infiltration

**Posted Date:** August 5th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-764282/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Journal of Neuroinflammation on February 18th, 2022. See the published version at <https://doi.org/10.1186/s12974-022-02415-z>.

# Abstract

**Background:** Multiple sclerosis (MS) is one of the most common autoimmune disorders characterized by the infiltration of immune cells into the brain and demyelination. The unwanted immunosuppressive side effect of therapeutically successful natalizumab led us to focus on choroid plexus (CP), a key site for the first wave of immune cell infiltration in experimental autoimmune encephalomyelitis (EAE), for the control of immune cells trafficking. Adenosine  $A_{2A}$  receptor ( $A_{2A}R$ ) is emerging as a potential pharmacological target to control EAE pathogenesis; however, the cellular basis for the  $A_{2A}R$ -mediated protection remains undetermined.

**Methods:** In EAE model, we assessed  $A_{2A}R$  expression and leukocyte trafficking determinants in CP by immunohistochemistry and qPCR analyses. We determined the effect of the  $A_{2A}R$  antagonist KW6002 treatment at days 8-12 or 8-14 post-immunization on T cell infiltration across CP and EAE pathology. We determined the critical role of the CP- $A_{2A}R$  on T cell infiltration and EAE pathology by focal knockdown the CP- $A_{2A}R$  with intracerebroventricular injection of CRE-TAT recombinase into the  $A_{2A}R^{fllox/fllox}$  mice. In cultured CP epithelium, we also evaluated the effect of overexpression of  $A_{2A}R$ s or the  $A_{2A}R$  agonist CGS21680 treatment on CP permeability and lymphocytes migration.

**Results:** We found the specific upregulation of  $A_{2A}R$  in CP in association with enhanced CP gateway activity peaked at day 12 post-immunization in EAE mice. Furthermore, the KW6002 treatment at days 8-12 or 8-14 post-immunization reduced T-cell trafficking across CP and attenuated EAE pathology. Importantly, focal CP- $A_{2A}R$  knockdown attenuated pathogenic infiltration of Th17<sup>+</sup> cells across CP via inhibiting CCR6-CCL20 axis through NF $\kappa$ B / STAT3 pathway and protected against EAE pathology. Lastly, activation of  $A_{2A}R$  in cultured epithelium by  $A_{2A}R$  overexpression or CGS21680 treatment increased the permeability of CP epithelium and facilitated lymphocytes migration.

**Conclusion:** These findings define the CP niche as one of the primary sites of  $A_{2A}R$  action whereby  $A_{2A}R$  antagonists confer protection against EAE pathology. Thus, pharmacological targeting of the CP- $A_{2A}R$  represents a novel therapeutic strategy for MS by controlling immune cell trafficking across CP.

## Introduction

Multiple sclerosis (MS) is one of the most common autoimmune disorders characterized by the over-activated immune system with immune infiltration, demyelination and subsequent defects in cognition, vision, motor and sensory sensitivity [1]. Experimental autoimmune encephalomyelitis (EAE) resembles the over-activated immune system in MS pathology with specific CD4<sup>+</sup> T helper cells response to myelin oligodendrocyte glycoprotein (MOG) antigen, and T cell infiltration, neuro-inflammation, demyelination, and hindlimb paralysis. The recognition of MS/EAE as an inflammatory disease, characterized by infiltration of immune cells into the brain has spurred an investigation into the development of immunomodulatory treatment and led to the approval of three classes of immunomodulatory drugs for

the treatment of MS, namely, 1) drugs depleting or impairing immune cells, 2) drugs modifying the activity of immune cells, and 3) drugs impairing the trafficking ability of lymphocytes into the brain [2, 3]. Among them, the natalizumab, an antibody directed against VLA-4, blocks leukocyte infiltration into the brain across the blood-brain barrier (BBB) and reduces the annualized MS relapse rate by about 70% [4]. The therapeutic success of natalizumab constitutes the best proof-of-principle for leukocyte trafficking blockade as a valid approach for treating of neuroinflammatory disease. Yet, this treatment is associated with an unanticipated life-threatening adverse effect (progressive multifocal leukoencephalopathy) and requires a strict monitoring program. Thus, search for alternative targets/strategies to control trans-epithelium/endothelium trafficking of immune cells into the brain is critically needed to develop an effective treatment of MS with better safety profile.

Immune cells infiltrate over cellular barriers into the CNS parenchyma through BBB and choroid plexus (CP). While many autoimmune studies have mainly focused on the transmigration of T lymphocytes through the blood-brain barrier (BBB), the choroid plexus (CP) is the primary site of entry for the EAE-inducing Th17 cells into the brain [5] and may act as a hub for the regulation of CNS immune homeostasis in MS pathology [5, 6]. The monolayer and continuous line of CP epithelium constitutes a tight junction (TJ) barrier preventing the entry of large molecules and maintaining the intracerebral homeostasis [7]. This CP epithelium lies in a connective and highly vascularized stroma populated by diverse cell types (fibroblasts, macrophages and dendritic cells). Increasing evidence supports that the choroid plexus is an essential route of immune cell entry. In MS/SPMS patients and optic neuritis patients, the cerebrospinal fluid (CSF) contains higher numbers of immune cells [8]; moreover such patients also display immune activation of the CP with mature immune cells in the CSF as evidenced by the increased expression of HLA-DR, CD86, CD80, and CD40 [9]. In the EAE model, immunization with myelin oligodendrocyte glycoprotein triggers the rapid accumulation of CD11C<sup>+</sup> immune cells in the CP, prior to onset of EAE clinical signs [9]. The immune cell infiltration across the CP is closely associated with altered expression of lymphocytes trafficking determinants in the CP [7, 10, 11]. Thus, the CP is a critical entry-point for immune cells in MS and targeting the CP gateway activity may represent an effective strategy for MS treatment.

This brings the adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>R), a potent regulator of neuroinflammation, in the CP into the focus of new therapeutic development for MS by controlling T cell infiltration. The study using positron emission tomography (PET) imaging with a radioligand to A<sub>2A</sub>R showed that A<sub>2A</sub>Rs are increased in the brain of secondary progressive multiple sclerosis (SPMS) patients [12]. The direct evidence for A<sub>2A</sub>R involvement in MS immunopathogenesis comes from our studies using EAE animals. We showed that the A<sub>2A</sub>R specific antagonist (SCH58261) and non-specific antagonist (caffeine) consistently attenuated EAE pathological process, in direct contrast to the A<sub>2A</sub>R-KO (knock out) observations [13–15]. However, genetic deletion of A<sub>2A</sub>R exacerbates the severity of EAE, with greater motor paralysis, more infiltrating CD4<sup>+</sup> T lymphocytes in the CNS, and more severe demyelination [16]. We further investigated this contradiction by a series of adoptive transfer experiments using the radiation bone marrow chimera model system in which A<sub>2A</sub>R activity in T lymphocytes promoted the severity of the inflammatory

response in EAE, while  $A_{2A}R$  activity on radiation-resistant, non-hematopoietic cells limited severe EAE pathology [17]. This explains that  $A_{2A}R$ s KO exacerbates EAE pathology largely attributed to the genetic deletion of  $A_{2A}R$  in lymphocytes with the promotion of inflammatory responses while pharmacological blockade of  $A_{2A}R$ s exerts control of EAE pathology via its action on non-hematopoietic cells. Critically, we noted that the choroid plexus epithelium (CPE) expresses a high level of mRNAs for  $A_{2A}R$  and CD73 (a 5'-nucleotidase converting AMP to extracellular adenosine and required for lymphocyte trafficking into the CNS), as revealed by fluorescence in situ hybridization (FISH) [17, 18]. The NECA (non-specific adenosine receptor agonist) regulates the expression of *cx3cl1*, which is causally linked to the protection against EAE induction as revealed by the CX3CL10 blocking antibody [19]. Thus, we proposed that the CP may represent the non-hematopoietic site where  $A_{2A}R$  antagonists control T cell infiltration and EAE pathology.

In this study, we found that  $A_{2A}R$  signal was upregulated in the CP tissues at day 8–12 post-immunization. In agreement with this time window, the selective treatment with the  $A_{2A}R$  antagonist KW6002 at post-immunization days 8–12 or 8–14 was sufficient to reduce T cell trafficking into the CNS across the CP and attenuate the brain damage. Importantly, selective depletion of  $A_{2A}R$  in the CP (by ICV injection of CRE-TAT recombinant protein in the  $A_{2A}R^{\text{flox/flox}}$  mice) reduced T cell trafficking into the CNS and alleviated EAE pathology by inhibiting CCR6-CCL20 axis through NF- $\kappa$ B/STAT3 pathway. This CP- $A_{2A}R$  effect was at least partially mediated by direct  $A_{2A}R$  action on the CP epithelium since boosted  $A_{2A}R$  signaling in the CP epithelium increased its permeability *in vitro* and facilitated T-cell migration *in vivo*. Collectively, these findings define the CP niche as one of the primary sites for  $A_{2A}R$  action, whereby  $A_{2A}R$  antagonist confers protection against EAE pathology. Thus, pharmacological targeting of the CP  $A_{2A}R$  represents a novel therapeutic strategy for MS treatment by controlling immune cell trafficking across the CP.

## Materials And Methods

### Animals

Eight-week-old C57BL/6 mice (female) were purchased from Charles River Laboratories (CRL, Beijing, China). The transgenic line B6. Cg-Gt (ROSA) 26Sor<sup>tm9</sup> (CAG-tdTomato) Hze/J (Ai9) was purchased from Jackson Laboratory (Stock No: 007909).  $A_{2A}R^{\text{flox/flox}}$  mice (female) have been described previously [20]. All mice were bred and housed under pathogen-free conditions at Wenzhou Medical University.

### EAE induction and behavioral scoring

EAE model was produced following the procedure described previously [16]. Briefly, 1:1 emulsion of MOG<sub>35-55</sub> peptide (1 mg/ml in PBS) (Anaspec) and complete Freund's adjuvant (CFA, Sigma) was injected subcutaneously (50  $\mu$ l) into each flank. In addition, pertussis toxin (PTX, 20 ng) (Biological Laboratories Inc.) was given intravenously (200  $\mu$ l in PBS) at the time of immunization and again two

days later. The EAE mice were daily scored based on the disease symptom severity scale (from 0 to 15), as we described previously [21].

### **In vivo assay of CP permeability**

Briefly, at day 8, 10, or 12 post-immunization, the EAE mice were anesthetized with 4.5% isoflurane and then treated with intravenous injection (retro-orbitally) of 100  $\mu$ l of 4 kDa Dextran Alexa Fluor 488 (final concentration 2 mg/100  $\mu$ l). Fifteen minutes later, the mice were deeply anesthetized with isoflurane and then perfused with cold PBS and 4% formaldehyde (PFA). The brains were dissected out and embedded with O.C.T. matrix. The frozen sections (20  $\mu$ m thick) were used to evaluate the fluorescence intensity with a confocal microscope (LSM880, Zeiss).

### **A<sub>2A</sub>R antagonist treatment**

For the treatment of the A<sub>2A</sub>R antagonist KW6002 *in vivo*, mice were intraperitoneally injected with vehicle (DMSO/PBS) or KW6002 (5 mg/kg) every day. To isolate the effective time window of KW6002, mice were intraperitoneally injected with vehicle (DMSO/PBS) or KW6002 (5 mg/kg) every day in the phase of day 8-14 or 8-12 post-immunization.

### **Over-expression of A<sub>2A</sub>R in the CP cell line ZM310**

The A<sub>2A</sub>R gene *Adora2a* (mouse, NM\_009630.3) was cloned into the vector FV115 (CMV-MCS-3Flag-Ubi-ZsGreen-IRES-Puromycin) with the seamless cloning method and was used for the lentivirus package ( $1.1 \times 10^8$ ). The empty vector was used as the control group.

The Z310 cells ( $2 \times 10^4$ ) were cultured in a DMEM medium (DMEM/F12 and 10% fetal bovine serum) at 37 °C for 24 h. The cells were then transfected with the constructed lentivirus (MOI (multiplicity of infection) = 20). Forty-eight hours following the transfection, the A<sub>2A</sub>R positive cells were screened with various concentrations of puromycin (1 $\mu$ g/ml, 2.5 $\mu$ g/ml, 5 $\mu$ g/ml, 10 $\mu$ g/ml). The ZsGreen positive cells were then used for TEER and cell migration assays.

### **Primary culture of the CP epithelium**

The CP cell cultures were produced as described previously [22]. Briefly, following perfusion with PBS, the CP tissues were dissected and digested with 0.25% trypsin. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/Ham's F12 medium (Invitrogen) containing 10% fetal bovine serum (FBS), 1 mM L-glutamine, 1 mM sodium pyruvate, penicillin/streptomycin (100 U/ml), insulin (5 ng/ml), 20  $\mu$ M arabinosylcytosine (Ara-C), sodium selenite (5 ng/ml), and epidermal growth factor (EGF) (10 ng/ml) (Sigma-Aldrich). Then, the cells were cultured in the L-polylysine-coated 24-well plates or polycarbonate filters according to the experimental goal.

### **Effects of CGS21680 and NF $\kappa$ B/STAT3 inhibitor**

Following cultivation of the abovementioned primary CP cells for three days, the cells were treated with CGS21680 (100 nM), or vehicle (DMSO). Then, 30 min later, the cells were collected for qPCR or Western Blot. In addition, the 3-days-cultured primary CP cells were pretreated with JSH-23 (10  $\mu$ M, a NF $\kappa$ B transcriptional activity inhibitor, 749886-87-1, Sigma-Aldrich), Stattic (100  $\mu$ M, a specific STAT3 inhibitor, 573099, Millipore) or vehicle for 1 h. Then, CGS21680 (100 nM, C141, Sigma-Aldrich) or vehicle were added. Finally, 30 min later, the cells were collected for qPCR.

### TEER measurement

The primary CP cells were isolated as described above and cultured on polycarbonate filters in a transwell chamber (pore size: 5  $\mu$ m, diameter: 6.5 mm). Six days later, the A<sub>2A</sub>R agonist CGS21680 (100 nM) was added into the upper chamber of the transwell. Then, TEER was monitored within 2 h (MERS00002, Millipore). For the rat CP epithelium cell line (ZM310), the A<sub>2A</sub>R-labelled, empty vector-labelled or blank ZM310 cells were cultured on the same filters for 4 days, then TEER was measured.

### T cell migration assay

The method was used as described previously [23]. Briefly, the A<sub>2A</sub>R-labelled, empty vector-labelled or blank ZM310 cells were grown on filters as mentioned above for 3 days. The CD4<sup>+</sup> T cells were isolated from the spleen with Anti-Mouse CD4 Magnetic Particles (BD, #551539). Then, the medium of the upper chamber was changed to 100  $\mu$ l 1640 medium containing CD4<sup>+</sup> T cells (1  $\times$  10<sup>6</sup> cells/ml), and the insert was plated into a new well filled with RPMI 1640 (0.5% FBS). Twenty-four hours later, the migrating cells in the lower chamber were subjected to the crystal violet staining and counted under a microscope (DM750, Leica).

### Quantitative real-time PCR (qPCR)

Following perfusion with PBS, the CP was dissected from the ventricles for RNA isolation using Trizol (Invitrogen) and cDNA synthesis with PrimeScript™ 1st Strand cDNA synthesis Kit (Takara, 6110A). Quantitative PCR was performed with SYBR-Green premix Extaq (Takara) and detected with a Real-Time PCR System (CFX96; Bio-Rad). The following primers were used: *ppia* (forward 5'-AGCATAACAGGTCCTGGCATCTTGT-3' and reverse 5'-CAAAGACCACATGCTTGCCATCCA-3'),

*icam1* (forward 5'-AGATCACATTCACGGTGCTGGCTA-3' and reverse 5'-AGCTTTGGGATGGTAGCTGGAAGA-3'),

*ccl2* (forward 5'-CATCCACGTGTTGGCTCA-3' and reverse 5'-GATCATCTTGCTGGTGAATGAGT-3'),

*cxcl10* (forward 5'-AACTGCATCCATATCGATGAC-3' and reverse 5'-GTGGCAATGATCTCAACAC-3'), *ccl5* (forward 5'-GCTGCTTTGCCTACCTCTCC-3' and reverse 5'-TCGAGTGACAAACACGACTGC-3'), *ccl20* (forward 5'-GCCTCTCGTACATACAGACGC-3' and reverse 5'-CCAGTTCTGCTTTGGATCAGC-3'), and

*adora2a* (forward, 5'-CCGAATTCCACTCCGGTACA-3' and, reverse 5'-CAGTTGTTCCAGCCCAGCAT-3');). The  $C_t$  values were converted to relative quantification data using a  $2^{-\Delta\Delta C_t}$  method.

### **Immunofluorescent and hematoxylin-eosin (HE) staining**

Anesthetized mice were fully perfused with PBS and 4% PFA (paraformaldehyde) and the brains were isolated and fixed with PFA. Before staining, the brain slices (30  $\mu$ m thick) were washed with PBS three times and then incubated for 30 min in PBS containing 0.3% Triton X-100 and 3% serum. Later, the slices were incubated with primary antibodies for 12 hours: rabbit anti-ICAM1 (1:100, Abcam) or mouse anti- $A_{2A}R$  (1:300, Wako). The sections were then washed with PBS and incubated for 2 h at room temperature with Alexa Fluor 488 antibodies (Abcam; 1:400). The slices were then washed and mounted on slides with VECTASHIELD mounting media (containing DAPI). For CD3 staining, the isolated CP tissues were fixed with 2.5% PFA for 30 min and then transferred to PBS. The following protocol was similar to the above procedure with rat anti-CD3 (1:100, CD3-FITC, Abcam). Images were acquired with a confocal microscope (LSM880, Zeiss).

As described earlier [16], tissue slices were stained with hematoxylin-eosin.

### **CP-specific knockdown of $A_{2A}Rs$**

The focal knockdown of  $A_{2A}Rs$  in the CP was achieved using the method described previously [24]. In brief, 2.11  $\mu$ l of CRE-TAT recombinase (20  $\mu$ g for each ventricle, Millipore) or sterile PBS were injected into each of the lateral ventricles (AP: 0.98, ML: -1.3, DV: 2.6). The injection rate was 1  $\mu$ l/min, and the needle was kept inside the brain for other 5 min before a withdrawal. Mice were allowed to recover for two weeks before the MOG immunization.

### **Flow cytometry analysis of immune cells**

Following perfusion with PBS, the spleen, CSF (5  $\mu$ l per mouse) and spinal cord were isolated from PBS or CRE-TAT treated mice at day 14 post immunization. Cell suspensions of the spleen and spinal cord were prepared and incubated with ACK buffer (C3702, Beyotime) to lyse red blood cells. With a centrifugation at 1500 rpm for 5 min, the cells were resuspended with 100  $\mu$ l of staining buffer (70-S1001, Multisciences). Next, 10  $\mu$ l of Clear Back (FcR blocking, MTG-001, MBL) were mixed with 50  $\mu$ l of cell suspension ( $\leq 1 \times 10^6$ ) and incubated for 5 min at room temperature. After that, 10  $\mu$ l of T-Select MHC Tetramer (I-A<sup>b</sup> MOG<sub>35-55</sub> Tetramer-PE, TS-M704-1, MBL) were added and incubated for 45 min at 4°C. Then, the samples were stained with fluorochrome-conjugated monoclonal antibodies against FVS510 (564406, BD Pharmingen), CD3-FITC (11-0032-82, Invitrogen), CD4-PerCP-Cy5.5 (550954, BD Pharmingen) and CD196-AF647 (561753, BD Pharmingen) for 30 min at 4°C. Next, the staining buffer (3 ml per sample) was added into the sample solution and mixed well. Following a centrifugation at 1500 rpm for 5 min, the cells were resuspended with 200  $\mu$ l of staining buffer. At last, the stained cells were acquired with a flow cytometer (NovoCyte Quanteon, Agilent) and analyzed with NovoExpress software (Agilent).

## Western Blot analysis of signaling molecules

The primary CP cells were isolated as started above and cultured in L-polylysine-coated plates for 2 days. Then, the cells were respectively treated with vehicle, 100 nM CGS21680 (HY-13201, MCE), 30  $\mu$ M JSH-23 (an inhibitor of nuclear translocation of p65) (HY-13982, MCE), 20  $\mu$ M Stattic (an inhibitor of STAT3 phosphorylation (Y705 and S727)) (HY-13818, MCE), a combination of JSH-23 (30  $\mu$ M) and CGS21680 (100 nM), or a combination of Stattic (20  $\mu$ M) and CGS21680 (100 nM). The cells were collected and prepared for RNA or protein isolation. The proteins were transferred from polyacrylamide gels to PVDF membranes (Invitrogen) at 100 V for 120 min. Membranes were blocked using bovine serum albumin (5% w/v). Membranes were incubated with primary antibodies overnight at 4 °C and secondary antibodies at room temperature for 90 min. Primary antibodies were anti-Stat3 (12640S, CST; 1:1000, rabbit), anti-Phospho-Stat3 (Tyr 705) (9145S, CST; 1:1000, rabbit), anti-NF $\kappa$ B-p65 (8242S, CST; 1:1000, rabbit) and anti-Phospho-NF $\kappa$ B-p65 (Ser 536) (3033S, CST; 1:1000, rabbit) (Ser 536) (9145S, CST; 1:1000, rabbit). The secondary antibody was IRDye 800CW (LICOR; 1:5000). Signal intensities were calculated using ImageJ software and normalized to values of Stat3 or p65.

## Statistical analyses

Statistical analysis of behavioral deficit scores in different groups during the EAE disease courses were determined utilizing Two-way ANOVA for repeated-measurements (RM). One-way ANOVA was used to estimate leukocyte trafficking determinant expression during EAE disease course. The Student's t-test was used to compare two groups of drug treatment, over-expression or CRE-TAT injection. All statistical analyses were performed with GraphPad Prism 6.0.

## Results

### The concordance of elevated A<sub>2A</sub>R signal and enhanced T cell infiltration in the CP during EAE

As CP is considered as the key site for the first wave of T cell trafficking into the brain [5], we firstly studied the expression of A<sub>2A</sub>R at different post-immunization time-points: day 0, 4, 8 (EAE pre-onset), 12 (ascent stage of pathology) and 16 (the peak season) by immunofluorescence staining (Fig. 1A-B). Interestingly, we found the low basal expression of A<sub>2A</sub>R (day 0) in the CP (Fig. 1A), comparable to that in the hippocampus and cortex [17], but contrast to the high expression level of A<sub>2A</sub>R in the striatum (Fig. S1) [25]. A<sub>2A</sub>R expression was visibly elevated in 8–16 days and peaked at day 12 (Fig. 1A and C). In parallel with the CP-A<sub>2A</sub>R expression, ICAM-1 (intercellular cell adhesion molecule-1), a ligand of LFA-1 (lymphocyte function-associated antigen-1), displayed similar expression patterns, with the peak expression at post-immunization day 12, suggesting the enhanced immune adhesion for leukocytes migration (Fig. 1A). Moreover, we studied the events of T lymphocytes trafficking into the CNS across the CP by CD3 antibody. We found that CD3<sup>+</sup> T cells dramatically aggregated in the CP at day 12 and the amount of CD3<sup>+</sup> T cells decreased at day 16 (Fig. 1A). There was also a detectable increase in the number of T cells in the CP at day 8 when the mice displayed no pathological scores (Fig. 1A).

Notably, T cell infiltration into the CNS through the CP happened probably earlier than through the BBB. H&E staining revealed leukocyte infiltration in the CP as early as post-immunization day 8 with peaked at post-immunization day 12 following EAE induction (Fig. S2A). By contrast, the “perivascular cuffs” (i.e., leukocyte cluster surrounding parenchyma vasculature) did not appear at brain parenchyma until day 12 (Fig. S2A). This early onset of CP/BCFB leakage compared to BBB was confirmed by dextran. After EAE induction, clear FITC signals were detected in the CP at day 8 and increased at day 10 and 12 (Fig. S2B). However, the FITC signals were nearly undetectable around the BBB in brain parenchyma at day 8 but gradually appeared at days 10 and 12 (Fig. S2B).

The qPCR analysis further suggested that  $A_{2A}R$  signals, as well as chemotaxis and adhesion molecules (*icam1*, *cxcl10* and *ccl5*) were up-regulated at days 8–16 (Fig. 1D-H). Following EAE induction, we isolated the PBS-perfused CPs at day 12. For each mouse, we determined the number of CD3<sup>+</sup> T cells in the CP from one hemisphere, and the  $A_{2A}R$  mRNA level in the CP from the other hemisphere. The regression analysis explicitly discovered the positive correlation between the number of T cells and mRNA level of  $A_{2A}R$  in the CP, indicating the functional linkage between abnormal  $A_{2A}R$  signal in CP and T cell trafficking (Fig. 1I). The parallel expression pattern and correlation analysis of the time window between  $A_{2A}R$  expression and immune infiltration through the CP suggest that elevated  $A_{2A}R$  signals (day 8–12) may facilitate T cell migration across the CP.

### **Selective treatment with the $A_{2A}R$ antagonist KW6002 at post-immunization day 8–12 inhibits T-cell infiltration into the CNS and EAE pathology**

Given the selective upregulation of  $A_{2A}R$  in parallel with the similar increase in leukocyte trafficking determinants and CD3<sup>+</sup> T cell infiltration in the CP, we proposed that the  $A_{2A}R$  antagonist may act on the CP to restrain the leukocyte infiltration across the CP and subsequently reduce brain damage. Firstly, after the MOG<sub>35–55</sub> immunization, mice were treated with an intraperitoneal injection (i.p.) of the  $A_{2A}R$  antagonist KW6002 or vehicle every day for 20 days. Consistent with a previous study [13], KW6002 treatment protected against EAE pathology as evident from the reduced clinical scores (Fig. 2A). We then isolated the PBS-perfused CPs at day 14 and stained them with a CD3 antibody. Notably, large numbers of CD3<sup>+</sup> T cells were detected in the CPs of the vehicle group, whereas few of CD3 positive signals were observed in the CPs of the KW6002-treated group (Fig. 2B). We also analyzed the leukocyte trafficking molecules (*icam1*, *cxcl10*, *ccl2* and *ccl5*) and found that the transcripts of *ccl5* and *cxcl10* were sharply suppressed by KW6002, while the *icam1* level did not show any changes (Fig. 2C-F).

Based on the finding mentioned above that the phase of infiltration across the CP was at days 8–16, we immunized the mice with MOG<sub>35–55</sub> and injection (i.p.) of KW6002 or vehicle at days 8–14 or 8–12 (i.e., the intense infiltration phase). We found that time-phase administration (days 8–14 or 8–12) of KW6002 also effectively protected mice from EAE pathology compared with the vehicle group (Fig. 2G-H). This selective KW6002 treatment decreased T cell trafficking across the CP (Fig. 2I-M) and reduced the

consequent mild immune infiltration in the spinal cord (Fig. 2N). This supported the idea that the CP is one of the key action sites of the A<sub>2A</sub>R antagonist against EAE pathology.

### **Tissue-specific knockdown of A<sub>2A</sub>R in the CP blunts its gateway activity and attenuates EAE pathology**

Systemic administration of KW6002 at a specific time window (with peak induction of A<sub>2A</sub>R) could not exclude the protective effects on sites other than the CP. Therefore, to isolate the CP as the key site for the A<sub>2A</sub>R-mediated protection in EAE pathology, we produced the local knockdown of A<sub>2A</sub>R in CP by ICV-injection of CRE-TAT recombinase to A<sub>2A</sub>R<sup>flox/flox</sup> transgenic line established in the lab. To confirm the CP-specificity of A<sub>2A</sub>R, we first injected the CRE-TAT protein into the lateral ventricles of mice expressing tdTomato fluorescent protein (RFP) under a loxP cassette. The analysis showed that the spontaneous red fluorescence was restricted to the ventricles and mainly located in the CP tissue (Fig. 3A).

Next, we performed ICV-injection of CRE-TAT into A<sub>2A</sub>R<sup>flox/flox</sup> mice and then isolated the CP for determining the A<sub>2A</sub>R ablation in CP after 2 weeks. The qPCR analysis showed that A<sub>2A</sub>R transcripts were reduced by about 50%, compared to the PBS-treated group (Fig. 3B). Following EAE induction with MOG<sub>35-55</sub> immunization, we found that the CP-A<sub>2A</sub>R knockdown mice just developed mild scores compared to the control group, consistent with the protective effect of KW6002 in the WT mice (Fig. 3C). Importantly, we found that CP-specific knockdown of A<sub>2A</sub>R prominently delayed the onset of EAE by 3 days, i.e., the first symptom detected at dpi (day post immunization) 14 in the A<sub>2A</sub>R knockdown group (Fig. 3C).

We further assessed the contribution of A<sub>2A</sub>R signal in the CP to the gating of lymphocyte infiltration for a pathological lesion. The qPCR analysis also displayed that chemokine (*ccl2*, *cxcl10*, and *ccl5*) expression was decreased following down-regulation of A<sub>2A</sub>R signal in the CP (Fig. 3D-G). CD3 staining of the CP tissues showed that blocking A<sub>2A</sub>R in the CP could effectively decrease T cell recruitment in the CP (Fig. 3H). Using H&E staining of the CP, we could observe dramatically reduced lymphocyte recruitment in the CP tissue and infiltration in the brain parenchyma, as well as the BBB leakage cued with no “perivascular cuffs” in the A<sub>2A</sub>R-knockdown group (Fig. 3I). Overall, these results indicated that blocking A<sub>2A</sub>R signal in the CP was sufficient to control the EAE pathological process.

### **A<sub>2A</sub>R signal in CP prevents Th17<sup>+</sup> T cells from infiltrating into the CSF via inhibiting CCR6-CCL20 axis**

During EAE induction, the CCR6-CCL20 axis was necessary for the first wave of Th17<sup>+</sup> T cells, which entered the CNS through the CP epithelium a crucial step in EAE pathology [26]. Furthermore, CCL20 was enriched on CP epithelium under healthy or EAE pathological conditions [5]. We next investigated whether KW6002 or CP-specific knockdown of A<sub>2A</sub>R inhibited the rolling of Th17<sup>+</sup> cells into the CNS across the CP by disturbing the CCR6-CCL20 axis. The immunohistochemical analysis showed that CCL20 was highly expressed in the CP at day 14 after EAE induction (Fig. 4A-B). Importantly, KW6002 administration (i.p.,

day 8–14) and the CP-specific knockdown of  $A_{2A}R$  largely abolished CCL20 upregulation in the CP (Fig. 4A-B).

We further determined the effect of CP- $A_{2A}R$  knockdown on Th17<sup>+</sup> infiltration across the CP. We first collected and analyzed the changes of Th17<sup>+</sup> T cells in the CSF by flow cytometry on the 14th day after EAE induction (Fig. 5A, Fig. S3). As expected, large numbers of Th17<sup>+</sup> T cells, existed in the CSF of the WT mice that developed EAE. However, only a handful of Th17<sup>+</sup> T cells was detected in the CSF of mice treated with TAT-CRE (Fig. 5A-B). Moreover, we evaluated the effect of the CP-specific knockdown of  $A_{2A}R$  on MOG<sub>35–55</sub>-specific Th17<sup>+</sup> T cells (a pathogenic immune cell population). Similarly, blocking  $A_{2A}R$  in the CP largely abolished infiltration of the MOG<sub>35–55</sub>-specific Th17<sup>+</sup> T cells in the CSF (Fig. 5C). Next, we investigated the effect of the CP-specific knockdown of  $A_{2A}R$  on the population of Th17<sup>+</sup> T cells in the spinal cord. Like the CSF effect, the numbers of both Th17<sup>+</sup> and MOG<sub>35–55</sub>-specific Th17<sup>+</sup> T cells were reduced in the CRE-TAT group compared to the control group (Fig. 5D-E). By contrast, the CP-specific knockdown of  $A_{2A}R$  did not alter the proportions and amount of Th17<sup>+</sup> and MOG<sub>35–55</sub>-specific Th17<sup>+</sup> T cells in the spleen (Fig. 5F-G). Collectively, these findings supported the idea that  $A_{2A}R$  signal in the CP prevented Th17<sup>+</sup> T cells from infiltrating into the CSF and the brain via CCR6-CCL20 axis.

### **Enhanced $A_{2A}R$ signaling in the CP epithelium induces chemokine activity and disrupts the tight junctions**

To find out whether  $A_{2A}R$  acts at the CP epithelium (from multiple cell types in the CP) to confer protection, we investigated the effect of  $A_{2A}R$  activity on chemokine signaling and tight junctions in the primary CP epithelium. We first probed the NF $\kappa$ B / STAT3 signaling mechanism of  $A_{2A}R$  regulating CCL20 by stimulating the  $A_{2A}R$  signal in the CP epithelium with the  $A_{2A}R$  agonist CGS21680. The western blot analysis revealed that CGS21680 treatment increased the level of phosphorylated p65 (Ser536) and STAT3 (Tyr705) compared to the vehicle group (Fig. 6A-D). In parallel with p65 (Ser536) and STAT3 (Tyr705), the level of *ccl20* mRNA was also induced by CGS21680 (Fig. 6E). Furthermore, we combined the inhibitor of NF $\kappa$ B or STAT3 pathway with CGS21680 and found that the up-regulation of *ccl20* induced by CGS21680 was abolished (Fig. 6E).

Next, we determined the effect of elevated  $A_{2A}R$  signal on the TJ function and leukocyte migration across the CP as TJ structure formed by the CP monolayer epithelium was the gateway to prevent the entry of macromolecules. We firstly overexpressed *Adora2a* (mouse, NM\_009630.3) in the CP epithelium cell line (rat, Z310) (Fig. 6F). We found that the overexpression of  $A_{2A}R$  significantly decreased the values of electrical resistance, which indicated that activation of  $A_{2A}R$  increased the permeability of TJ (Fig. 6G). Moreover, the trans-epithelial migration assay revealed that increased  $A_{2A}R$  signal facilitated the migration of T lymphocytes across epithelial barriers (Fig. 6H-I). In addition, after culturing the murine primary CP epithelium for 5 days, the  $A_{2A}R$  agonist CGS21680 was added into the upper and lower chambers. The dynamic curves showed that the permeability of epithelium was rapidly increased within 1

h (Fig. 6J). This suggested that elevated  $A_{2A}R$  in the CP could compromise TJ integrity and facilitate lymphocyte trafficking in EAE.

## Discussion

Identification and characterization of the effective molecular targets in the CP to control the heightened influx of immune cells across the CP are essential to elucidate the initial mechanisms driving MS pathogenesis and may lead to a novel pharmacological strategy for controlling autoimmune damage to CNS tissues. Our finding identifies  $A_{2A}R$  signaling in the CP niche as a key controller for T cell trafficking and EAE pathology. (i) Following  $MOG_{35-55}$  immunization, phase (i.e., day 8–14 post immunization) of elevated  $A_{2A}R$  expression coincided with the early T cell infiltration across the CP and attenuated behavioral deficit in the EAE mice. (ii) Consistent with the peak  $A_{2A}R$  expression window, the  $A_{2A}R$  antagonist KW6002 (administered at post-immunization day 8–12 or 8–14) markedly reduced the EAE-induced infiltration of  $CD3^+$  T cells across the CP and attenuated behavioral deficit in the EAE mice. (iii) By targeted deletion of  $A_{2A}R$  in the CP by local injection of CRE-TAT recombinant protein into the  $A_{2A}R^{flox/flox}$  mice, we found that the CP-specific knockdown of  $A_{2A}R$  effectively reduced the infiltration of  $Th17^+$  cells in the CSF and spinal cord and delayed the onset of EAE behavioral deficit and ameliorated the scores. This was accomplished by CP- $A_{2A}R$  modulation of the expression of *ccl20* in the CP epithelium. (iv)  $A_{2A}R$  control of the CP gateway activity is at least partially mediated by direct action on the CP epithelium since activation of  $A_{2A}R$  signal (by overexpression or agonist) in the CP epithelium increased the permeability and facilitated lymphocytes migration, in agreement with the previous study showing that the  $A_{2A}R$  agonist promotes lymphocyte transmigration across CPLacZ-2 cells[19]. (v) Blocking  $A_{2A}R$  signal in the CP can prevent  $Th17^+$  T cells from infiltrating into the CSF by inhibiting CCR6-CCL20 axis and NF $\kappa$ B/STAT3 pathway. Collectively, these findings defined (abnormally elevated)  $A_{2A}R$  signaling in the CP niche as a critical modulator for the CP gateway activity whereby lymphocytes infiltrated into the CNS via BCSFB route during the first wave of T cell infiltration in EAE development. These findings further solidify the essential role of the CP gateway activity in EAE development, particularly the first wave of T cell infiltration.

The identification of the CP  $A_{2A}R$  activity controlling the CP gateway and EAE pathology also provides partial resolution for the paradoxical (opposite) effects of  $A_{2A}R$  knockout and  $A_{2A}R$  antagonist on EAE pathology. Moreover, this finding identified  $A_{2A}R$  in the CP as the source of non-hematopoietic cells that confer the  $A_{2A}R$ -mediated protection as revealed by adoptive transfer experiment [17]. While the protective effect of the  $A_{2A}R$  antagonists (SCH58261 and caffeine) has been well demonstrated in the EAE model [13, 14], the paradoxical exacerbation of EAE pathology by  $A_{2A}R$  KO complicated the therapeutic development of selectively targeting  $A_{2A}R$  [16]. Notably,  $A_{2A}R$  antagonists protect against EAE pathology even in the presence of pro-inflammatory  $A_{2A}R^{-/-}$   $CD4^+$  T cells as administering the  $A_{2A}R$  antagonist SCH58261 protected against EAE pathology following the adoptive transfer of WT or  $A_{2A}R^{-/-}$   $CD4^+$  T

cells into the  $A_{2A}R^{+/+}$  TCR-deficient mice [17]. Our finding that targeted deletion of  $A_{2A}R$  in the CP protects mice from EAE induction provides a direct evidence that the protective effects of  $A_{2A}R$  antagonists on non-hematopoietic cells are likely mediated by  $A_{2A}R$  signaling in the CP, which modulates the lymphocyte migration into the CNS.

Critically, we demonstrated that the timing of  $A_{2A}R$  administration (post-immunization day 8–12) is critical for the successful treatment of MS by  $A_{2A}R$  antagonists. The leukocyte trafficking across the CP was considered to be the first wave of T cell trafficking in EAE development (not an initiation of autoimmune response).  $A_{2A}R$  signaling has been shown to play a distinct role at the different stages of EAE developmental course. Specifically, during the initiation stage, (post-MOG immunization day 0–10), administering an  $A_{2A}R$  agonist on dpi 0–14 conferred protection while SCH58261 administration on day 0–10 displayed no protective effect [13, 23](). Adoptive transfer experiments demonstrated that the mechanism of such protection ( $A_{2A}R$  agonist effect) to be the downregulated inflammatory potential of  $A_{2A}R$ -expressing lymphocytes [23]. During EAE disease progression, administering  $A_{2A}R$  antagonist on day 11–28 (peak of symptomatic disease) conferred protection while administering the  $A_{2A}R$  agonist had a detrimental effect [13, 23]. However, this disease progression stage is characterized by two steps in disease development: the first wave of encephalitogenic Th17 cells infiltration into the CNS via the CP epithelium in a CCL20-dependent gradient, and the subsequent recruitment of both encephalitogenic T cells and bystander cells, such as macrophages occurs via the BBB (postcapillary venules) within the brain parenchyma. Importantly, two lines of our experimental findings further narrow the effective therapeutic window of KW6002 to the day 8–12 for protection against EAE pathology: (i) there was specific peak induction of  $A_{2A}R$  expression in the CP around dpi 12, in agreement with the up-regulation of CD73 [18] and CGS21680-regulated CX3CL1 expression [19] at this time window; (ii) administration of KW6002 selectively during the acute stage (i.e., day 8–12) can alleviate pathology with the reduced immune infiltration across the CP. Thus, systemic administration of KW6002 at the specific acute stage in EAE (dpi 8–12), namely the time window with the intense T-cell infiltration across the CP, may effectively confer protection as offered by KW6002 treatment throughout the entire disease progression course. This strongly argues that the CP niche is one of the critical sites where KW6002 controls the first wave of blood lymphocytes migration into the CSF, which may, in turn, weaken the BBB destruction by pro-inflammatory factors from the CSF. This also suggests that systemic administration of KW6002 at this specific time window (with enhanced CP  $A_{2A}R$  signaling) may be sufficient to accomplish selective targeting of the CP- $A_{2A}R$ .

Identifying the ability of the CP  $A_{2A}R$  signaling to control the CP gateway for T cell trafficking confers  $A_{2A}R$  antagonists an ability to protect against EAE pathology by directly targeting the CP epithelium (to control immune cell trafficking, rather than immune cell activity directly). The clinical studies have demonstrated the clinical effectiveness of the natalizumab to control immune infiltration for clinical MS treatment by blocking the binding between VLA-4 and VCAM [2]. Notably, all of these FDA-approved MS drugs are designed to directly target immune cells, which may completely inhibit lymphocyte migration.

Such complete inhibition may be associated with the consequential induction of temporary immunodeficiency in patients, such as the increased risk of progressive multifocal leukoencephalopathy (PML) and other opportunistic infections [27]. Blockade of A<sub>2A</sub>R signaling reduced the expression of *ccl20* and inhibited the CCR6-CCL20 axis in the CP via the NFκB / STAT3 signaling cascade. This indirect modulation of chemotaxis (CCR6-CCL20) and adhesion molecules in the choroid plexus may offer a better approach to treating MS by selectively interfere with the recruitment of pathogenic leukocytes to the CNS while leaving host protective immune mechanisms intact (i.e., by inhibiting certain, but not all, lymphocyte subsets from entering the CNS). Thus, the identification of the CP A<sub>2A</sub>R activity to control the CP epithelium for T cell trafficking and EAE pathology supports the novel strategy for alleviating EAE pathology solely by targeting the CP epithelium activity, rather than directly targeting immune cell activity, to avoid the unwanted side effects. The recent approval of the A<sub>2A</sub>R antagonist Nourianz<sup>®</sup> (istradefylline) by the U.S. Food and Drug Administration (FDA) as an add-on treatment to levodopa in Parkinson's disease (PD) with "OFF" episodes in 2019 [28] have demonstrated its noted safety profile and clinical utility. This approval offers new therapeutic opportunities for translating A<sub>2A</sub>R antagonist for the disease-modifying treatment of MS.

## Conclusion

This study provides the direct evidence in establishing a critical role of the CP-A<sub>2A</sub>R in control of T cell infiltration and EAE pathology: (i) A<sub>2A</sub>R signal was upregulated in the CP tissues at day 8–12 post-immunization, correlating with the increased CP gateway activity and T cell infiltration across CP; (ii) the selective treatment with the A<sub>2A</sub>R antagonist KW6002 at post-immunization days 8–12 or 8–14 was sufficient to reduce T cell trafficking across the CP and attenuate EAE pathology; (iii) selective knockdown of A<sub>2A</sub>Rs in the CP attenuated Th17 cells infiltration and alleviated EAE pathology; (iv) CP-A<sub>2A</sub>R controlled T cell trafficking by inhibiting CCR6-CCL20 axis, partially by direct A<sub>2A</sub>R action on the CP epithelium. Collectively, these findings define the CP niche as one of the primary sites for A<sub>2A</sub>R antagonist to confer protection against EAE pathology. Thus, pharmacological targeting of the CP-A<sub>2A</sub>R represents a novel treatment strategy for MS by controlling immune cell trafficking across the CP.

## Declarations

### Acknowledgements

Not applicable

### Authors' contributions

J.F. Chen and W. Zheng conceived and designed the experiments and wrote the article; Y.J. Feng, W. Zheng, Z.H. Zeng, M.Q. Ye, H.P. Shang, M.R. Wang, Z.Z. Li, X.T. Sun, X.Y. W, W. Guo and X.X. Lin performed the experiments; W. Zheng, Y.J. Feng and W. Liu analyzed the data.

## Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 31800903, No. 81630040), the Science Foundation of Zhejiang province, China (Grant No. LQ18H090007), the National Key Research and Development Program of China (Grant No. 2016YFC1306600, No. 2016YFC1306602), the Start-up Fund from Wenzhou Medical University (Grant No. 89211010, No. 89212012), Wenzhou Science and Technology Project (Grant No. Y2020426).

## Availability of data and materials

The data used in this study are available from the corresponding author on reasonable request.

## Ethics approval and consent to participate

The animal protocols contained herein were approved by the Institutional Ethics Committee for Animal Use in Research and Education at Wenzhou Medical University, China.

## Consent for publication

Not applicable

## Competing interests

The authors declare that they have no conflict of interest.


## References

1. Reich, D., C. Lucchinetti, and P. Calabresi. Multiple Sclerosis. *N Engl J Med.* 2018; **378**(2): 169-180. <https://doi.org/10.1056/NEJMra1401483>.
2. Dendrou, C. and L. Fugger. Immunomodulation in multiple sclerosis: promises and pitfalls. *Curr Opin Immunol.* 2017; **49**: 37-43. <https://doi.org/10.1016/j.coi.2017.08.013>.
3. Thompson, A. and O. Ciccarelli. Towards treating progressive multiple sclerosis. *Nat Rev Neurol.* 2020; **16**(11): 589-590. <https://doi.org/10.1038/s41582-020-00421-4>.
4. Polman, C., P. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. Miller, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med.* 2006; **354**(9): 899-910. <https://doi.org/10.1056/NEJMoa044397>.
5. Reboldi, A., C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli, S. Lira, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. *Nat Immunol.* 2009; **10**(5): 514-23. <https://doi.org/10.1038/ni.1716>.
6. Breuer, J., E. Korpos, M. Hannocks, T. Schneider-Hohendorf, J. Song, L. Zondler, et al. Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus. *J Neuroinflammation.* 2018; **15**(1): 236. <https://doi.org/10.1186/s12974-018-1276-4>.

7. Meeker, R.B., K. Williams, D.A. Killebrew, and L.C. Hudson. Cell trafficking through the choroid plexus. *Cell Adh Migr*. 2012; **6**(5): 390-6. <https://doi.org/10.4161/cam.21054>.
8. Cepok, S., M. Jacobsen, S. Schock, B. Omer, S. Jaekel, I. Böddeker, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. *Brain*. 2001; **124**: 2169-76. <https://doi.org/10.1093/brain/124.11.2169>.
9. Serafini, B., S. Columba-Cabezas, F. Di Rosa, and F. Aloisi. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. *Am J Pathol*. 2000; **157**(6): 1991-2002. [https://doi.org/10.1016/S0002-9440\(10\)64838-9](https://doi.org/10.1016/S0002-9440(10)64838-9).
10. Baruch, K. and M. Schwartz, CNS-specific T cells shape brain function via the choroid plexus. *Brain Behav Immun*. 2013; **34**: 11-6. <https://doi.org/10.1016/j.bbi.2013.04.002>.
11. Shechter, R., O. Miller, G. Yovel, N. Rosenzweig, A. London, J. Ruckh, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. *Immunity*. 2013; **38**(3): 555-69. <https://doi.org/10.1016/j.immuni.2013.02.012>.
12. Rissanen, E., J. Virta, T. Paavilainen, J. Tuisku, S. Helin, P. Luoto, et al. Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study. *J Cereb Blood Flow Metab*. 2013; **33**(9): 1394-401. <https://doi.org/10.1038/jcbfm.2013.85>.
13. Chen, Y., Z. Zhang, L. Zheng, L. Wang, Y. Liu, W. Yin, et al. The adenosine A receptor antagonist SCH58261 reduces macrophage/microglia activation and protects against experimental autoimmune encephalomyelitis in mice. *Neurochem Int*. 2019; **129**: 104490. <https://doi.org/10.1016/j.neuint.2019.104490>.
14. Wang, T., N. Xi, Y. Chen, X. Shang, Q. Hu, J. Chen, et al. Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism. *Neuropharmacology*. 2014; **86**: 203-11. <https://doi.org/10.1016/j.neuropharm.2014.06.029>.
15. Chen, G., Y. Chen, X. Wang, S. Wu, H. Yang, H. Xu, et al. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. *Brain Res*. 2010; **1309**: 116-25. <https://doi.org/10.1016/j.brainres.2009.10.054>.
16. Yao, S., Z. Li, Q. Huang, F. Li, Z. Wang, E. Augusto, et al. Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis. *J Neurochem*. 2012; **123**(1): 100-12. <https://doi.org/10.1111/j.1471-4159.2012.07807.x>.
17. Mills, J., D. Kim, A. Krenz, J. Chen, and M. Bynoe. A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. *J Immunol*. 2012; **188**(11): 5713-22. <https://doi.org/10.4049/jimmunol.1200545>.
18. Mills, J., L. Thompson, C. Mueller, A. Waickman, S. Jalkanen, J. Niemela, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci U S A*. 2008; **105**(27): 9325-30. <https://doi.org/10.1073/pnas.0711175105>.

19. Mills, J., L. Alabanza, D. Mahamed, and M. Bynoe. Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis. *J Neuroinflammation*. 2012; **9**: 193. <https://doi.org/10.1186/1742-2094-9-193>.
20. Bastia, E., Y. Xu, A. Scibelli, Y. Day, J. Linden, J. Chen, et al. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. *Neuropsychopharmacology*. 2005; **30**(5): 891-900. <https://doi.org/10.1038/sj.npp.1300630>.
21. Weaver, A., A. Goncalves da Silva, R. Nuttall, D. Edwards, S. Shapiro, S. Rivest, et al. An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. *FASEB J*. 2005; **19**(12): 1668-70. <https://doi.org/10.1096/fj.04-2030fje>.
22. Kunis, G., K. Baruch, N. Rosenzweig, A. Kertser, O. Miller, T. Berkutzki, et al. IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. *Brain*. 2013; **136**(P11): 3427-40. <https://doi.org/10.1093/brain/awt259>.
23. Ingwersen, J., B. Wingerath, J. Graf, K. Lepka, M. Hofrichter, F. Schröter, et al. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. *J Neuroinflammation*. 2016; **13**: 48. <https://doi.org/10.1186/s12974-016-0512-z>.
24. Kertser, A., K. Baruch, A. Deczkowska, A. Weiner, T. Croese, M. Kenigsbuch, et al. Corticosteroid signaling at the brain-immune interface impedes coping with severe psychological stress. *Sci Adv*. 2019; **5**(5): eaav4111. <https://doi.org/10.1126/sciadv.aav4111>.
25. JF, C., E. HK, and F. BB Adenosine receptors as drug targets—what are the challenges? *Nat Rev Drug Discov*. 2013; **12**(4): 265-86. <https://doi.org/10.1038/nrd3955>.
26. Luger, D., P. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. *J Exp Med*. 2008; **205**(4): 799-810. <https://doi.org/10.1084/jem.20071258>.
27. Hauser, S. and B. Cree. Treatment of Multiple Sclerosis: A Review. *The Am J Med*. 2020; **133**(12): 1380-1390.e2. <https://doi.org/10.1016/j.amjmed.2020.05.049>.
28. Chen, J. and R. Cunha. The belated US FDA approval of the adenosine A receptor antagonist istradefylline for treatment of Parkinson's disease. *Purinergic signal*. 2020; **16**(2): 167-174. <https://doi.org/10.1007/s11302-020-09694-2>.


## Figures



**Figure 1**


A2AR signals located on the choroid plexus were increased in the EAE model. A Following EAE induction in WT mice, the immunofluorescent staining of A2AR, ICAM1 and CD3 was performed at days 0, 4, 8, 12, and 16 after immunization. Scale bar, 100  $\mu$ m (n = 3/group). B The clinical scores of EAE mice in Fig. 1A (n = 20). C The fluorescence quantification of A2AR in Fig. 1A (n = 3/group). One-Way ANOVA, Tukey's multiple comparisons test. D-H The mRNA analysis of adora2a (A2AR), icam1, ccl2, ccl5 and cxcl10 at

days 0, 4, 8, 12, and 16 post immunization. I Regression analysis between the numbers of CD3+ T cells recruited to the CP tissue and mRNA level of adora2a (A2AR). \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$  and \*\*\*  $p \leq 0.001$ .




**Figure 2**

A2AR antagonist KW6002 attenuated EAE pathology in mice. A Full-phase injection (i.p.) of KW6002 decreased the clinical scores of EAE (n = 7/group). Two-Way RM (repeated measures) ANOVA, Sidak's multiple comparisons test. B Full-phase injection (i.p.) of KW6002 reduced the recruitment of CD3+ T cells on the CP (n = 3/group) at day 12 post immunization. C-F Full-phase injection (i.p.) of KW6002 down-regulated the mRNA levels of ccl5 and cxcl10 (n = 3/group). Unpaired t test. G Injection (i.p.) of KW6002 (day post immunization (dpi) 8-14) reduced the clinical scores of EAE (n = 9/group). Two-Way RM ANOVA, Sidak's multiple comparisons test. H Injection (i.p.) of KW6002 (dpi 8-12) reduced the clinical scores of EAE (n = 7/group). Two-Way RM ANOVA, Sidak's multiple comparisons test. I Injection (i.p.) of KW6002 (dpi 8-14) reduced the recruitment of CD3+ T cells to the CP (n = 3/group) at day 12 after immunization. J-M Injection (i.p.) of KW6002 (dpi 8-14) down-regulated the mRNA levels of ccl5, ccl2 and cxcl10 (n = 3/group). Unpaired t test. N At dpi 14, the H&E staining of spinal cords from EAE mice injected (i.p.) with KW6002 or vehicle (dpi 8-14) (n = 3/group). ##  $p \leq 0.01$ , ###  $p \leq 0.001$ , \*  $p \leq 0.05$ , \*\*  $p \leq 0.01$  and \*\*\*  $p \leq 0.001$ .




**Figure 3**

Knockdown of A2AR expression in the CP attenuated EAE pathology. A Representative image of tdTomato flox/flox mice intracerebroventricularly (ICV) injected with CRE-TAT recombinant protein. Two weeks later, the expression of tdTomato was restricted to the CP (n = 3/group). B Two weeks after ICV-injection of TAT-CRE into A2AR flox/flox mice, the expression of A2AR in the CP was notably knocked down (n = 3/group). Unpaired t test. C Specific knock-down of A2AR in the CP reduces the clinical scores (n = 5-6/group). Two-Way RM ANOVA, Sidak's multiple comparisons test. D-G Specific knock-down of A2AR in the CP reduced the expressions of ccl5, ccl2, and cxcl10 (n = 3/PBS group and n = 5/CRE-TAT group). Unpaired t test. H Specific knock-down of A2AR in the CP reduced the recruitment of CD3<sup>+</sup> T cells to the CP at day 12 post immunization (n = 3/group). I The H&E staining showed that specific knock down of A2AR in the CP attenuated the infiltration of immune cells in the CP at day 12 after immunization (n = 3/group). ### p < 0.001, \* p < 0.05, \*\* p < 0.01 and \*\*\* p < 0.001.




**Figure 4**

Knockdown of A2AR expression in the CP reduced the expression of CCL20. A Injection (i.p.) of KW6002 (dpi 8-14) reduced the expression of on CP (n = 3/group) at day 14 after immunization (n = 3/group). B specific knock-down of A2AR in the CP inhibited the expression of CCL20 in CP at day 14 after immunization (n = 3/group).



**Figure 5**

Knockdown of A2AR expression in the CP inhibited the infiltration of Th17<sup>+</sup> T cells. A Following knockdown of A2AR signal in the CP and EAE induction, flow cytometry was performed to analyze the number of Th17<sup>+</sup> or MOG<sub>35-55</sub> specific Th17<sup>+</sup> T cells in the CSF, spinal cords, and spleen. B-C Knockdown of A2AR expression in the CP reduced the infiltration of Th17<sup>+</sup> or MOG<sub>35-55</sub> specific Th17<sup>+</sup> T cells in the CSF (n = 3/group). Unpaired t test. D-E Knockdown of A2AR expression in the CP reduced the infiltration of Th17<sup>+</sup> or MOG<sub>35-55</sub> specific Th17<sup>+</sup> T cells in the spinal cord (n = 3/group). Unpaired t test. F-G Knockdown of A2AR expression in the CP did not alter the number of Th17<sup>+</sup> or MOG<sub>35-55</sub> specific Th17<sup>+</sup> T cells in the spleen (n = 3/group). Unpaired t test. \* p<0.05 and \*\* p<0.01.



**Figure 6**

Elevation of A2AR signal in the CP epithelium increased the permeability and promoted the migration of T cells. A-B In the primary CP epithelium, the A2AR agonist CGS21680 increased the phosphorylation level of STAT3 (n = 3/group). C-D In the primary CP epithelium, the A2AR agonist CGS21680 also increased the phosphorylation level of p65 (n = 3/group). E NFκB transcriptional activity inhibitor (JSH-23, 10 μM) and specific STAT3 inhibitor (Stattic, 100 μM) abolished the increased expression of ccl20 induced by CGS21680 in the primary CP epithelium (n = 3/group). F Representative image of ZsGreen-labeled A2ARs overexpressed in the Z310 cell line. G Over-expression of A2AR increased the resistance value of Z310 cells (n = 3/group). Unpaired t test. H-I Over-expression of A2AR promoted the migration of CD4<sup>+</sup> T cells across the Z310 cell layer (n = 3/group). Unpaired t test. J Following the addition of CGS21680 into the medium, the resistance values of the primary CP epithelium were monitored in real-time within 2 h (n = 3/group). One-way RM ANOVA, Dunnett's multiple comparisons test. ## p<0.01, \* p<0.05 and \*\* p<0.01. "p" stands for phosphorylation.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Fig.S1.tif](#)
- [Fig.S2.tif](#)

- Fig.S3.tif
- Fig.S4.tif